Change in injecting behaviour among people treated for hepatitis C virus

the role of intimate partnerships

, Amy Malaguti (Lead / Corresponding author), Fabio Sani, Brian P. Stephens, Farsana Ahmad, Patricia Dugard, John Dillon

Research output: Contribution to journalArticle

1 Citation (Scopus)
3 Downloads (Pure)

Abstract

Injecting behaviour in people who inject drugs is the main risk factor for hepatitis C virus (HCV) infection. Psychosocial factors such as having a partner who injects drugs and living with other drug users have been associated with increases in injecting risk behaviour. This study aimed to investigate changes in injecting behaviour during treatment for HCV infection whilst exploring the role of psychosocial factors on patients’ injecting behaviour. Eradicate-C was a single-centred clinical trial (ISRCTN27564683) investigating the effectiveness of HCV treatment within the injecting drug-using population between 2012 and 2017. A total of 94 participants completed up to 24 weeks of treatment, with social and behavioural measures taken at different intervals throughout treatment. Data for 84 participants were analysed retrospectively to explore mechanisms of potential behavioural changes which had occurred during treatment. Injecting frequency reduced significantly between baseline (week 1) and every 4-weekly interval until week 26. Not being on opiate substitution therapy (OST) was associated with a statistically significant decrease in injecting frequency, χ 2 (1) = 10.412, P = 0.001, as was having a partner who also used drugs, in particular when that partner was also on treatment for HCV infection, Z = −2.312, P = 0.021. Treating a hard-to-reach population for HCV infection is not only possible, but also bears health benefits beyond treatment of HCV alone. Enrolling couples on HCV treatment when partners are sero-concordant has shown enhanced benefits for reduction in injecting behaviour. Implications for practice are discussed.

Original languageEnglish
Pages (from-to)65-72
Number of pages8
JournalJournal of Viral Hepatitis
Volume26
Issue number1
Early online date27 Sep 2018
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Hepacivirus
Virus Diseases
Therapeutics
Pharmaceutical Preparations
Opiate Alkaloids
Psychology
Insurance Benefits
Risk-Taking
Drug Users
Population
Clinical Trials

Keywords

  • Hepatitis C
  • People who inject drugs
  • Injecting behaviour
  • Partner
  • Opiate substitution therapy
  • opiate substitution therapy
  • partner
  • hepatitis C
  • injecting behaviour
  • people who inject drugs

Cite this

@article{e23c2b0849a5408fbb81edee13b2e81f,
title = "Change in injecting behaviour among people treated for hepatitis C virus: the role of intimate partnerships",
abstract = "Injecting behaviour in people who inject drugs is the main risk factor for hepatitis C virus (HCV) infection. Psychosocial factors such as having a partner who injects drugs and living with other drug users have been associated with increases in injecting risk behaviour. This study aimed to investigate changes in injecting behaviour during treatment for HCV infection whilst exploring the role of psychosocial factors on patients’ injecting behaviour. Eradicate-C was a single-centred clinical trial (ISRCTN27564683) investigating the effectiveness of HCV treatment within the injecting drug-using population between 2012 and 2017. A total of 94 participants completed up to 24 weeks of treatment, with social and behavioural measures taken at different intervals throughout treatment. Data for 84 participants were analysed retrospectively to explore mechanisms of potential behavioural changes which had occurred during treatment. Injecting frequency reduced significantly between baseline (week 1) and every 4-weekly interval until week 26. Not being on opiate substitution therapy (OST) was associated with a statistically significant decrease in injecting frequency, χ 2 (1) = 10.412, P = 0.001, as was having a partner who also used drugs, in particular when that partner was also on treatment for HCV infection, Z = −2.312, P = 0.021. Treating a hard-to-reach population for HCV infection is not only possible, but also bears health benefits beyond treatment of HCV alone. Enrolling couples on HCV treatment when partners are sero-concordant has shown enhanced benefits for reduction in injecting behaviour. Implications for practice are discussed.",
keywords = "Hepatitis C, People who inject drugs, Injecting behaviour, Partner, Opiate substitution therapy, opiate substitution therapy, partner, hepatitis C, injecting behaviour, people who inject drugs",
author = "Amy Malaguti and Fabio Sani and Stephens, {Brian P.} and Farsana Ahmad and Patricia Dugard and John Dillon",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/jvh.13009",
language = "English",
volume = "26",
pages = "65--72",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley",
number = "1",

}

Change in injecting behaviour among people treated for hepatitis C virus : the role of intimate partnerships. / ; Malaguti, Amy (Lead / Corresponding author); Sani, Fabio; Stephens, Brian P.; Ahmad, Farsana; Dugard, Patricia; Dillon, John.

In: Journal of Viral Hepatitis, Vol. 26, No. 1, 01.01.2019, p. 65-72.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Change in injecting behaviour among people treated for hepatitis C virus

T2 - the role of intimate partnerships

AU - Malaguti, Amy

AU - Sani, Fabio

AU - Stephens, Brian P.

AU - Ahmad, Farsana

AU - Dugard, Patricia

AU - Dillon, John

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Injecting behaviour in people who inject drugs is the main risk factor for hepatitis C virus (HCV) infection. Psychosocial factors such as having a partner who injects drugs and living with other drug users have been associated with increases in injecting risk behaviour. This study aimed to investigate changes in injecting behaviour during treatment for HCV infection whilst exploring the role of psychosocial factors on patients’ injecting behaviour. Eradicate-C was a single-centred clinical trial (ISRCTN27564683) investigating the effectiveness of HCV treatment within the injecting drug-using population between 2012 and 2017. A total of 94 participants completed up to 24 weeks of treatment, with social and behavioural measures taken at different intervals throughout treatment. Data for 84 participants were analysed retrospectively to explore mechanisms of potential behavioural changes which had occurred during treatment. Injecting frequency reduced significantly between baseline (week 1) and every 4-weekly interval until week 26. Not being on opiate substitution therapy (OST) was associated with a statistically significant decrease in injecting frequency, χ 2 (1) = 10.412, P = 0.001, as was having a partner who also used drugs, in particular when that partner was also on treatment for HCV infection, Z = −2.312, P = 0.021. Treating a hard-to-reach population for HCV infection is not only possible, but also bears health benefits beyond treatment of HCV alone. Enrolling couples on HCV treatment when partners are sero-concordant has shown enhanced benefits for reduction in injecting behaviour. Implications for practice are discussed.

AB - Injecting behaviour in people who inject drugs is the main risk factor for hepatitis C virus (HCV) infection. Psychosocial factors such as having a partner who injects drugs and living with other drug users have been associated with increases in injecting risk behaviour. This study aimed to investigate changes in injecting behaviour during treatment for HCV infection whilst exploring the role of psychosocial factors on patients’ injecting behaviour. Eradicate-C was a single-centred clinical trial (ISRCTN27564683) investigating the effectiveness of HCV treatment within the injecting drug-using population between 2012 and 2017. A total of 94 participants completed up to 24 weeks of treatment, with social and behavioural measures taken at different intervals throughout treatment. Data for 84 participants were analysed retrospectively to explore mechanisms of potential behavioural changes which had occurred during treatment. Injecting frequency reduced significantly between baseline (week 1) and every 4-weekly interval until week 26. Not being on opiate substitution therapy (OST) was associated with a statistically significant decrease in injecting frequency, χ 2 (1) = 10.412, P = 0.001, as was having a partner who also used drugs, in particular when that partner was also on treatment for HCV infection, Z = −2.312, P = 0.021. Treating a hard-to-reach population for HCV infection is not only possible, but also bears health benefits beyond treatment of HCV alone. Enrolling couples on HCV treatment when partners are sero-concordant has shown enhanced benefits for reduction in injecting behaviour. Implications for practice are discussed.

KW - Hepatitis C

KW - People who inject drugs

KW - Injecting behaviour

KW - Partner

KW - Opiate substitution therapy

KW - opiate substitution therapy

KW - partner

KW - hepatitis C

KW - injecting behaviour

KW - people who inject drugs

UR - http://www.scopus.com/inward/record.url?scp=85055549023&partnerID=8YFLogxK

U2 - 10.1111/jvh.13009

DO - 10.1111/jvh.13009

M3 - Article

VL - 26

SP - 65

EP - 72

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 1

ER -